Schizophrenia Clinical Trials in New York, New York

13 studies are recruiting for schizophrenia in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. 52-week Open Label Safety-Tolerability Study

   Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neuro-Behavioral Clinical Research, New York, New York

   Locations

   23 in total

   Run by

   LB Pharmaceuticals Inc.

   See if you can join NCT07369154 on ClinicalTrials.gov

2. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   Adams Clinical Harlem, New York, New York

   Locations

   103 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

3. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, New York, New York

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

4. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

   This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   NYU Child Study Center, New York, New York

   Locations

   64 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06229210 on ClinicalTrials.gov

5. Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

   The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

   Stage

   Not phased

   Ages

   18 and older

   Site

   Radial - Manhattan, New York, New York

   Locations

   20 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07101094 on ClinicalTrials.gov

6. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

   To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

   Stage

   Phase 3

   Ages

   10 to 17

   Site

   Alkermes Investigator Site, New York, New York

   Locations

   47 in total

   Run by

   Alkermes, Inc.

   See if you can join NCT05303064 on ClinicalTrials.gov

7. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

   This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, New York, New York

   Locations

   57 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07114874 on ClinicalTrials.gov

8. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

   The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, New York, New York

   Locations

   20 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07227818 on ClinicalTrials.gov

9. Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

   Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine the effects of treatment with clozapine vs antipsychotic treatment as usual (TAU) for reducing the …

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   NYU Langone Medical Center, New York, New York

   Locations

   7 in total

   Run by

   New York State Psychiatric Institute

   See if you can join NCT05208190 on ClinicalTrials.gov

10. Study of ALTO-101 in Patients With Schizophrenia

    This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerabil…

    Stage

    Phase 2

    Ages

    21 to 55

    Site

    Site 5108, New York, New York

    Locations

    14 in total

    Run by

    Alto Neuroscience

    See if you can join NCT06502964 on ClinicalTrials.gov

11. Effectiveness of Motivation Skills Training (MST)

    This study will take place at four outpatient clinics serving adults with serious mental illness. Informed consent will be obtained from N=80 individuals with a Diagnostic and Statistical Manual of Mental Illnesses (DSM)-5 diagnosis of schizophrenia or schizoaffective disorder meeting inclusion/exc…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    The Bridge, Inc., New York, New York

    Locations

    2 in total

    Run by

    Columbia University

    See if you can join NCT05805397 on ClinicalTrials.gov

12. Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

    The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.

    Stage

    Phase 3

    Ages

    13 to 17

    Site

    Manhattan Behavioral Medicine PLLC, New York, New York

    Locations

    57 in total

    Run by

    Gedeon Richter Plc.

    See if you can join NCT03817502 on ClinicalTrials.gov

13. Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study

    This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms…

    Stage

    Not phased

    Ages

    18 to 60

    Site

    Zucker Hillside Hospital, New York, New York

    Run by

    Northwell Health

    See if you can join NCT05389787 on ClinicalTrials.gov